Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)
Randomised, double-blind, placebo-controlled crossover Phase I study (n=16) testing pre-treatment with doxazosin versus placebo on physiological and subjective responses to a single oral MDMA 125 mg dose in healthy volunteers.
Details
This randomized double-blind placebo-controlled crossover study in 16 healthy volunteers tests whether alpha1-adrenergic blockade with doxazosin attenuates the cardiovascular and subjective effects of MDMA (single oral 125 mg).
Doxazosin is given as a pre-treatment regimen across three days before each MDMA session; subjective and cardiovascular measures are recorded repeatedly and plasma samples collected for pharmacokinetics.
Primary outcome focuses on blood pressure response; secondary measures include heart rate, subjective effects and adverse events.